Literature DB >> 14555991

Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function.

Frederic Luciano1, Arnaud Jacquel, Pascal Colosetti, Magali Herrant, Sebastien Cagnol, Gilles Pages, Patrick Auberger.   

Abstract

Bim is a proapoptotic member of the Bcl-2 family that shares only the BH3 domain with this family. Three Bim proteins Bim-EL, Bim-L and Bim-S are synthesized from the same transcript. We report here that Bim-EL when phosphorylated by Erk1/2 is rapidly degraded via the proteasome pathway. Using different cellular models we evidence that serine 69 is both necessary and sufficient for Erk1/2-mediated phosphorylation and degradation of Bim-EL. In K562 cells, Phorbol 12-myristate 13-acetate activates Erk1/2 and consequently increases Bim-EL phosphorylation and degradation by the proteasome, resulting in cell survival, while the Bcr-Abl inhibitor imatinib abrogates Bim-EL phosphorylation and degradation and induces caspase activation and apoptosis. We also show that Bim-EL(S69G) promotes apoptosis more efficiently than Bim-EL-WT in K562 cells. Altogether, our findings demonstrate that phosphorylation of Bim-EL by Erk1/2 on serine 69 selectively leads to its proteasomal degradation and therefore represents a new and important mechanism of Bim regulation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14555991     DOI: 10.1038/sj.onc.1206792

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  202 in total

Review 1.  Cytokine-mediated cell survival.

Authors:  Toshiya Inaba
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490

2.  Alternative splicing of Bim and Erk-mediated Bim(EL) phosphorylation are dispensable for hematopoietic homeostasis in vivo.

Authors:  C Clybouw; D Merino; T Nebl; F Masson; M Robati; L O'Reilly; A Hübner; R J Davis; A Strasser; P Bouillet
Journal:  Cell Death Differ       Date:  2012-01-13       Impact factor: 15.828

3.  ERK1 is important for Th2 differentiation and development of experimental asthma.

Authors:  Nicholas Goplen; Zunayet Karim; Lei Guo; Yonghua Zhuang; Hua Huang; Magdalena M Gorska; Erwin Gelfand; Gilles Pagés; Jacques Pouysségur; Rafeul Alam
Journal:  FASEB J       Date:  2012-01-18       Impact factor: 5.191

4.  Up-regulation of pro-apoptotic protein Bim and down-regulation of anti-apoptotic protein Mcl-1 cooperatively mediate enhanced tumor cell death induced by the combination of ERK kinase (MEK) inhibitor and microtubule inhibitor.

Authors:  Takumi Kawabata; Susumu Tanimura; Kohei Asai; Ryohei Kawasaki; Yumi Matsumaru; Michiaki Kohno
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

Review 5.  Proteasome inhibitors in mantle cell lymphoma.

Authors:  Beata Holkova; Steven Grant
Journal:  Best Pract Res Clin Haematol       Date:  2012-05-16       Impact factor: 3.020

6.  Differences underlying EGFR and HER2 oncogene addiction.

Authors:  Anthony C Faber; Kwok-Kin Wong; Jeffrey A Engelman
Journal:  Cell Cycle       Date:  2010-03-30       Impact factor: 4.534

7.  The major isoforms of Bim contribute to distinct biological activities that govern the processes of autophagy and apoptosis in interleukin-7 dependent lymphocytes.

Authors:  Shannon M Ruppert; Wenqing Li; Ge Zhang; Adina L Carlson; Arati Limaye; Scott K Durum; Annette R Khaled
Journal:  Biochim Biophys Acta       Date:  2012-06-21

8.  Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.

Authors:  Chaoyang Sun; Yong Fang; Jun Yin; Jian Chen; Zhenlin Ju; Dong Zhang; Xiaohua Chen; Christopher P Vellano; Kang Jin Jeong; Patrick Kwok-Shing Ng; Agda Karina B Eterovic; Neil H Bhola; Yiling Lu; Shannon N Westin; Jennifer R Grandis; Shiaw-Yih Lin; Kenneth L Scott; Guang Peng; Joan Brugge; Gordon B Mills
Journal:  Sci Transl Med       Date:  2017-05-31       Impact factor: 17.956

9.  EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance.

Authors:  Shuijie Li; Javier Rodriguez; Wenyu Li; Petra Bullova; Stuart M Fell; Olga Surova; Isabelle Westerlund; Danijal Topcic; Maria Bergsland; Adam Stenman; Jonas Muhr; Monica Nistér; Johan Holmberg; C Christofer Juhlin; Catharina Larsson; Alex von Kriegsheim; William G Kaelin; Susanne Schlisio
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-02       Impact factor: 11.205

10.  Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability.

Authors:  D-W Wu; C-Y Chen; C-L Chu; H Lee
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.